All News about Lexaria Bioscience Corp WT
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria Provides Annual Letter From the CEO
January 27, 2022
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
December 16, 2021
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
December 14, 2021
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
December 08, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
November 03, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
November 01, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
October 13, 2021
Via CannabisNewsWire
Topics
Cannabis
Exposures
Cannabis
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria's Technology Proven to Deliver Oral THC More Effectively
October 13, 2021
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
October 05, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
July 29, 2021
Via AccessWire
Topics
Intellectual Property
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
Lexaria Receives US$3,817,643 From Warrant Exercises
July 26, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
Lexaria Receives Patent Protection in Japan
July 13, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.